ANIK:NSD-Anika Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 39.99

Change

-1.07 (-2.61)%

Market Cap

USD 0.59B

Volume

0.32M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-3.28 (-1.62%)

USD81.30B 135.70 104.16
REGN Regeneron Pharmaceuticals, Inc

+1.91 (+0.36%)

USD57.11B 15.26 11.77
BNTX BioNTech SE

-1.78 (-0.83%)

USD49.23B -99,999.99 35.63
VRTX Vertex Pharmaceuticals Incorpo..

-0.51 (-0.27%)

USD48.76B 17.95 12.38
ALXN Alexion Pharmaceuticals, Inc

+0.72 (+0.40%)

USD39.91B 58.41 42.10
BGNE BeiGene, Ltd

-7.33 (-2.23%)

USD30.29B N/A N/A
GMAB Genmab A/S

-0.61 (-1.40%)

USD29.17B 26.59 3.71
SGEN Seagen Inc

+2.93 (+1.91%)

USD27.46B 42.22 39.29
RPRX Royalty Pharma plc

-0.11 (-0.25%)

USD26.79B 22.60 15.62
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ANIK

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.64% 38% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.64% 38% F 18% F
Trailing 12 Months  
Capital Gain 16.49% 59% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.49% 59% F 33% F
Trailing 5 Years  
Capital Gain -18.55% 43% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.55% 43% F 18% F
Average Annual (5 Year Horizon)  
Capital Gain -0.82% 31% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.82% 31% F 20% F
Risk Return Profile  
Volatility (Standard Deviation) 30.55% 86% B 58% F
Risk Adjusted Return -2.69% 30% F 21% F
Market Capitalization 0.59B 58% F 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.00 20% F 25% F
Price/Book Ratio 2.18 78% C+ 61% D-
Price / Cash Flow Ratio 45.23 4% F 11% F
EV/EBITDA 60.38 14% F 15% F
Management Effectiveness  
Return on Equity -9.45% 89% B+ 42% F
Return on Invested Capital -3.50% 83% B 39% F
Return on Assets -0.83% 91% A- 43% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 18.55 4% F 2% F
Short Percent 11.82% 23% F 15% F
Beta 1.22 59% F 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector